Literature DB >> 27679836

Comparison of hypertrophic cardiomyopathy in Afro-Caribbean versus white patients in the UK.

Nabeel Sheikh1,2, Michael Papadakis1,2, Vasileios F Panoulas3, Keerthi Prakash1,2, Lynne Millar1,2, Paolo Adami4, Abbas Zaidi1,2, Sabiha Gati1,2, Mathew Wilson5, Gerald Carr-White6, Maria Teresa Esteban Tomé1, Elijah R Behr1, Sanjay Sharma1,2.   

Abstract

BACKGROUND: This study investigated the influence of African/Afro-Caribbean (black) ethnicity on the clinical profile and outcomes in hypertrophic cardiomyopathy (HCM).
METHODS: 425 consecutive patients with HCM (163 black and 262 Caucasians (white); mean age 52.5±16.6 years) were assessed at three cardiomyopathy centres. Repeat assessments were performed every 6-12 months and mean follow-up was 4.3±3.0 years. The primary outcome was a composite of cardiovascular death, cardiac arrest or appropriate device therapy.
RESULTS: A fortuitous diagnosis of HCM was more commonly made in black compared with white patients (31.3% vs 19.1%, p=0.004). An abnormal ECG at presentation was more frequent in black patients (98.2% vs 90.5%, p=0.002), with T-wave inversion being a common feature (91.4% vs 73.0%, p<0.001). Asymmetric septal hypertrophy was the predominant pattern in both ethnic groups; however, apical (22.2% vs 10.7%, p<0.001) and concentric (9.3% vs 1.5%, p<0.001) patterns were more prevalent in black patients. Hypertension was more frequent in black patients (58.3% vs 31.7%, p<0.001). There were no ethnic differences in risk factor profile or primary outcome. Independent predictors of the primary outcome were non-sustained ventricular tachycardia (HR 6.03, 95% CI 3.06 to 11.91, p≤0.001) and hypertension at presentation (HR 2.02, 95% CI 1.05 to 3.88, p=0.036), with an additive effect.
CONCLUSION: Black ethnicity is an important determinant of the phenotypic expression of HCM but does not adversely affect outcomes. Apical and concentric hypertrophy are common in black patients and may hinder the identification of HCM in this cohort. Hypertension has an adverse effect on outcome, irrespective of ethnicity. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Year:  2016        PMID: 27679836     DOI: 10.1136/heartjnl-2016-309843

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  12 in total

Review 1.  Precisely Where Are We Going? Charting the New Terrain of Precision Prevention.

Authors:  Karen M Meagher; Michelle L McGowan; Richard A Settersten; Jennifer R Fishman; Eric T Juengst
Journal:  Annu Rev Genomics Hum Genet       Date:  2017-04-24       Impact factor: 8.929

Review 2.  Racial disparities in ventricular tachycardia in young adults: analysis of national trends.

Authors:  Harsh P Patel; Samarthkumar Thakkar; Nishaki Mehta; Mohammed Faisaluddin; Rezwan F Munshi; Ashish Kumar; Safi U Khan; Rohan Parikh; Christopher V DeSimone; Garima Sharma; Abhishek Deshmukh; Khurram Nasir; Sarju Ganatra; Sourbha S Dani
Journal:  J Interv Card Electrophysiol       Date:  2022-08-10       Impact factor: 1.759

3.  Incidence of recreational sports-related sudden cardiac arrest in participants over age 12 in a general African population.

Authors:  Gladys M K Tchanana; Marcus Ngantcha; Matthew F Yuyun; Olujimi A Ajijola; Samuel Mbouh; Steve C T Tchameni; Ahmed Suliman; Aimé Bonny
Journal:  BMJ Open Sport Exerc Med       Date:  2020-08-23

4.  INDUCED PLURIPOTENT STEM CELLS FOR MODELLING ENERGETIC ALTERATIONS IN HYPERTROPHIC CARDIOMYOPATHY.

Authors:  Chrishan J A Ramachandra; K P Myu Mai Ja; Ying-Hsi Lin; Winston Shim; William A Boisvert; Derek J Hausenloy
Journal:  Cond Med       Date:  2019

Review 5.  Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy.

Authors:  Gherardo Finocchiaro; Emma Magavern; Gianfranco Sinagra; Euan Ashley; Michael Papadakis; Maite Tome-Esteban; Sanjay Sharma; Iacopo Olivotto
Journal:  J Am Heart Assoc       Date:  2017-12-13       Impact factor: 5.501

6.  Disease Expression and Outcomes in Black and White Adults With Hypertrophic Cardiomyopathy.

Authors:  Milla E Arabadjian; Gary Yu; Mark V Sherrid; Victoria Vaughan Dickson
Journal:  J Am Heart Assoc       Date:  2021-08-25       Impact factor: 5.501

Review 7.  Hypertrophic Cardiomyopathy: Updates Through the Lens of Sports Cardiology.

Authors:  Bradley S Lander; Dermot M Phelan; Matthew W Martinez; Elizabeth H Dineen
Journal:  Curr Treat Options Cardiovasc Med       Date:  2021-05-25

Review 8.  Disparities in the Diagnosis of Hypertrophic Obstructive Cardiomyopathy: A Narrative Review of Current Literature.

Authors:  Joseph Burns; Philippe Jean-Pierre
Journal:  Cardiol Res Pract       Date:  2018-10-02       Impact factor: 1.866

9.  Ventricular Arrhythmia in Septal and Apical Hypertrophic Cardiomyopathy: The French-Canadian Experience.

Authors:  Christian Steinberg; Charles Nadeau-Routhier; Philippe André; François Philippon; Jean-François Sarrazin; Isabelle Nault; Gilles O'Hara; Louis Blier; Franck Molin; Benoit Plourde; Karine Roy; Eric Larose; Marie Arsenault; Jean Champagne
Journal:  Front Cardiovasc Med       Date:  2020-10-22

Review 10.  Exercise and hypertrophic cardiomyopathy: Two incompatible entities?

Authors:  Joyee Basu; Aneil Malhotra; Michael Papadakis
Journal:  Clin Cardiol       Date:  2020-02-12       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.